Department of Gastroenterology, Affiliated Hospital of Xuzhou Medical University, Xuzhou Jiangsu, China.
Institute of Digestive Diseases, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Cancer Control. 2020 Apr-Jun;27(2):1073274820922559. doi: 10.1177/1073274820922559.
Gastric cancer (GC) is fifth most frequently diagnosed cancer and second leading cause of cancer in China. More than 80% of GC are diagnosed at an advanced stage due to low uptake rate of invasive screening method. The performance of methylated test was evaluated in 236 plasma samples, including 92 patients with GC, 16 intestinal metaplasia patients, 26 gastric fundic gland polyp patients, 13 small adenoma patients, 39 hyperplastic polyp patients, and 50 control patients. The sensitivity of plasma methylated was compared to serum CEA, CA72-4, CA19-9, and CA242 results in 79 patients with GC. The sensitivities for detecting GC and gastric intestinal metaplasia by methylated test were 60.9% and 56.3% with a specificity of 86.0%. Methylated test had significantly higher positive detection rate for patients with GC than gastric fundic gland polyp, small adenoma, and hyperplastic polyp patients. In 79 patients with GC, the sensitivities of CEA, CA72-4, CA19-9, and CA242 for detecting GC were 22.8%, 16.5%, 12.7%, and 11.4%. In comparison, the sensitivity of methylated test for detecting GC was 58.2%. Plasma methylated test may become a valuable tool for the noninvasive detection of GC and precursor lesions and showed higher sensitivity than serum tumor markers.
胃癌（GC）是全球第五大常见癌症，也是中国第二大癌症死因。由于侵入性筛查方法的接受率低，超过 80%的胃癌患者在晚期才被诊断出来。在 236 份血浆样本中评估了甲基化测试的性能，其中包括 92 名胃癌患者、16 名肠上皮化生患者、26 名胃底腺息肉患者、13 名小腺瘤患者、39 名增生性息肉患者和 50 名对照患者。在 79 名胃癌患者中，将血浆甲基化测试的敏感性与血清 CEA、CA72-4、CA19-9 和 CA242 结果进行了比较。甲基化测试检测胃癌和胃肠上皮化生的敏感性分别为 60.9%和 56.3%，特异性为 86.0%。甲基化测试对胃癌患者的阳性检出率明显高于胃底腺息肉、小腺瘤和增生性息肉患者。在 79 名胃癌患者中，CEA、CA72-4、CA19-9 和 CA242 检测胃癌的敏感性分别为 22.8%、16.5%、12.7%和 11.4%。相比之下，甲基化测试检测胃癌的敏感性为 58.2%。血浆甲基化测试可能成为非侵入性检测胃癌及其前体病变的有价值工具，其敏感性高于血清肿瘤标志物。
